Pappas Capital Announces the Passing of…

Monmouth Junction, NJ, (April 13, 2010) -- TYRX, Inc. announced today the commercial release of the AIGISRx® Flat, an antibacterial product that helps provide protection against infections associated with implanted pacemakers and defibrillators.

Like the original AIGISRx™ Envelope, AIGISRx Flat delivers the anti-microbial agents, rifampin and minocycline which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm management device (CRMD)-related endocarditis, including “superbugs” or MRSA. AIGISRx Flat also offers the implanting physician additional flexibility in the application of these lifesaving devices.